Spiegel Online manager-magazin.de

Sonntag, 21. Juli 2019

Börse

BUSINESS WIRE: Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

19.06.2019, 14:30 Uhr

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

-- Collaboration will Leverage Nurix's Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets --

FOSTER CITY, Calif. & SAN FRANCISCO --(BUSINESS WIRE)-- 19.06.2019 --

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body's natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005092/en/

Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix's technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells.

Anzeige

Under the multi-year collaboration, Nurix will utilize its proprietary drug discovery platform to identify novel agents that utilize E3 ligases to induce degradation of specified drug targets and Gilead will have an option to license drug candidates directed to up to five targets resulting from the work. Nurix will retain the option to co-develop and co-detail up to two programs in the United States. The collaboration excludes Nurix's lead degradation program, for which Nurix retains all rights.

"There are many molecular targets involved in disease pathways that have traditionally been challenging to manipulate using conventional approaches," said John McHutchison, A.O., M.D., Chief Scientific Officer and Head of Research and Development, Gilead Sciences. "Nurix's innovative protein degradation discovery technology provides Gilead with a new strategy to interrogate these drug targets, as we continue to build a pipeline of small molecule therapeutics for patients with cancers and other diseases."

"Gilead is an ideal partner to help us bring potentially transformative treatments to patients," said Arthur T. Sands, M.D., Ph.D., Nurix's Chief Executive Officer. "This partnership expands our ability to build our pipeline of novel targeted protein degradation drugs based on our established expertise in the field of protein homeostasis, while we continue to independently advance our lead programs into the clinic."

Under the terms of the agreement, Nurix will receive an upfront payment of $45 million and will be eligible to receive up to approximately $2.3 billion in total additional payments based on the successful completion of certain research, pre-clinical, clinical, regulatory and commercialization milestones as well as up to low double-digit tiered royalties on net sales. For those programs that Nurix opts in to co-develop and co-detail, the parties will split development costs as well as profits and losses 50/50 for the U.S., and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.

About Nurix Therapeutics, Inc.

Nurix discovers drugs that harness the body's natural process to control protein levels. Nurix' pipeline is focused on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally-recognized experts in E3 ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix-inc.com.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of cancer and other diseases. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead Contacts:
Sung Lee, Investors
(650) 524-7792

Nathan Kaiser, Media
(650) 522-1853

Nurix Contact:
Sara Zelkovic, Media
(646) 876-4933

Weitere Nachrichten

19.07. IRW-PRESS: MGX Minerals Inc.: MGX Minerals meldet Zulassung zur Notierung seiner Tochtergesellschaft MGX Renewables Inc. an Canadian Securities Exchange
19.07. IRW-PRESS: Benchmark Metals Inc.: Benchmark beginnt im Gold-Silber-Konzessionsgebiet Lawyers mit Explorations- und Bohrarbeiten
19.07. IRW-PRESS: aktiencheck.de AG: Neuer 417% Pot Hot Stock erwartet 1,12 Mrd. $ Umsatz und 525 Mio. $ operativen Gewinn - Wettbewerber 33 mal höher bewertet. Bester Cannabis Aktientip nach 50.000% mit Aurora Cannabis und 294.900% mit Canopy Growth – AC - Rese
19.07. IRW-PRESS: Cape Lambert Resources Limited: Klärende Mitteilung
19.07. BUSINESS WIRE: Geschäftszahlen 1. Halbjahr 2019: Sartorius setzt zweistelliges Wachstum fort
19.07. BUSINESS WIRE: MoEngage zum zweiten Mal in Folge im Gartner Magic Quadrant 2019 für Mobile-Marketing-Plattformen aufgeführt
19.07. GlobeNewswire: Bizagi geht von einem eher unauffälligen Auftreten zu rasantem Wachstum über und liefert digitale Transformation für weltweit führende Marken
19.07. BUSINESS WIRE: Toshiba Memory heißt ab Oktober „Kioxia“
19.07. BUSINESS WIRE: Transphorm-Webinar: Verständnis der Qualität und Zuverlässigkeit von Hochspannungs-GaN-FETs in Energieanwendungen
18.07. BUSINESS WIRE: Rekapitalisierung von Quotient Sciences mit der globalen Private-Equity-Firma Permira
Anzeige
Anzeige